Cormorant Asset Management, LP Bluebird Bio, Inc. Transaction History

Cormorant Asset Management, LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2018 May 15, 2018	SELL	$105.8 - $150.94 $8.46 Million - $12.1 Million	-80,000 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$81.25 - $130.7 $4.67 Million - $7.52 Million	-57,500 Reduced 41.82%	80,000 $14.2 Million
Q3 2017 Nov 14, 2017	BUY	$57.74 - $91.42 $7.94 Million - $12.6 Million	137,500	137,500 $18.9 Million

173

104M

827K

1.23M

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $75.6M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.